How to Buy Adma Biologics Stock
Adma Biologics Inc
ADMA Biologics, Inc. , a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Adma Biologics stock last closed at $18.71, up 0.21% from the previous day, and has increased 214.98% in one year. It has overperformed other stocks in the Biotechnology industry by 2.96 percentage points. Adma Biologics stock is currently +217.39% from its 52-week low of $5.90, and -20.85% from its 52-week high of $23.64.
There are currently 236.39M ADMA shares outstanding. The market cap of ADMA is $4.42B. In the past 24 hours, 2.72M ADMA shares were traded.
How to Buy Adma Biologics Stock
Not sure how to invest in Adma Biologics stock? Here's how.
- Choose where to buy Adma Biologics stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you choose where to buy Adma Biologics stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your brokerage account: Select your payment method and add your information.
- Research Adma Biologics stock: The Adma Biologics ticker symbol is ADMA. Is Adma Biologics stock a good investment? Should you buy shares of ADMA? How do ADMA's underlying business fundamentals look? Do top analysts think Adma Biologics is a good buy? Why has ADMA's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if ADMA is a good stock to buy).
- Make your ADMA buy order: Decide if you will purchase ADMA shares at the current market price or use a limit order to buy ADMA stock at a given price.
- Get key alerts regarding your ADMA investment: Create a watchlist to monitor your position in Adma Biologics stock.
Step 1: Choose where to buy Adma Biologics stock
You will need a brokerage account in order to access the NASDAQ market and buy ADMA shares.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Technology to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've selected the best brokerage, the next step is to fill out some personal details so you are able to invest in ADMA today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to create a new brokerage account.
- Submit your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you have finished signing up on the best investment app, you can securely and quickly fund your account:
Check out the walkthrough below for more details depositing funds into your new brokerage account.
Step 4: Research Adma Biologics stock
Once you have selected the best place to buy Adma Biologics stock, it's absolutely critical to evaluate their stock prior to investing, so you truly comprehend the risk as well as the opportunity.
Overview of key ADMA info
ADMA Fundamentals
WallStreetZen was built to help everyday investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on ADMA's stock page.
Is ADMA stock undervalued or overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge ADMA's intrinsic value.
Using relative valuations metrics:
- ADMA may be undervalued based on its P/E ratio of 64.52x, relative to Biotechnology industry P/E ratio of -110.15x
- ADMA could be overvalued based on its P/B ratio of 19.07x, relative to Biotechnology industry P/B ratio of 4.74x
- ADMA could be overvalued based on its PEG ratio of 1.12x
You can access additional valuation analysis on ADMA's stock here.
A quick look at ADMA Financials
Passed Financial Due Diligence Checks:
- There are more short-term assets than short-term liabilities on the ADMA balance sheet.
- There are more short-term assets than long-term liabilities on the ADMA balance sheet.
- ADMA earnings of $90.62M is not sufficient to cover its interest payments.
- Total ADMA debt is lower than 5 years ago, relative to shareholder equity.
- ADMA profit margin has gone up from -9.7% to 17.8% in the past year.
- ADMA's operating cash flow of $86.05M allows it to safely service it's debt of $102.52M.
Failed Financial Due Diligence Checks:
- ADMA has a relatively high debt to equity ratio of 0.68.
Is Adma Biologics stock a Buy, Hold, or Sell, according to analysts?
Out of 3 sell side analysts who track ADMA, the consensus analyst rating on Adma Biologics is a Strong Buy
It's important to note that analyst forecasts are not recommendations, nor are they investment advice.
You can dig deeper into what analysts are projecting on the Adma Biologics stock forecast page.
ADMA Trading Indicators
ADMA Performance Metrics
Last year, ADMA revenue was $382.81M. During the past 5 year, ADMA's revenue has grown by 78.09% per year. This was faster than the Biotechnology industry average of 44.95%.
Learn more about ADMA's earnings and revenue performance here.
Latest Insiders Trades at ADMA
In the past year, insiders at ADMA have sold more shares than they have bought.
Adam S. Grossman, President and CEO of ADMA, was the latest ADMA insider to sell. They sold $502,311.26 worth of ADMA shares on Mar 7, 2025.
Research more about who owns ADMA stock here.
Does ADMA stock generate passive income?
No, Adma Biologics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your ADMA buy order
You have two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually fine. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific price limit, place a limit order.
Hit the Open Trade button and eToro will execute your order.
If you require additional info about buying stocks on eToro, watch the how to video below:
Step 6: Get key alerts regarding your ADMA investment
Now that you own some ADMA shares, you'll want to stay up-to-date on your new company.
Add ADMA to a watchlist to get notified of the latest news about your ADMA stock.
ADMA Feed
How to Buy Stock in Adma Biologics
To summarize, here are the 6 steps to buy stock in Adma Biologics:
- Choose where to buy Adma Biologics stock
- Sign up for a brokerage account
- Deposit money your brokerage account
- Research Adma Biologics stock
- Make your ADMA buy order
- Get key alerts regarding your ADMA investment
If you are looking for a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest news on your new investment in Adma Biologics, click below.
More Articles You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.